

28 January 2021


Announcements  
Australian Securities Exchange  
20 Bridge Street  
SYDNEY NSW 2000

**2020 Annual General Meeting – Chairman's Address**

A copy of the Chairman's address is attached, which will be presented at the Company's Annual General Meeting tomorrow in Sydney, 29 January 2021.

This announcement has been authorised for release by the board of directors of the Company.

For and on Behalf of The Board of iQ3Corp Limited.



Aysha Hollingdale  
Company Secretary  
Tel: 02 8239 5400

**CHAIRMAN'S SCRIPT**  
**Annual General Meeting**  
**iQ3 Corp Limited**  
**Friday 29<sup>th</sup> January 2021 – 10:00am**

**(CHAIRMAN'S ADDRESS)**

On behalf of the Board of Directors, I am pleased to report that the team has continued to successfully progress the work to implement the strategy and objectives of iQ3Corp Limited (**iQ3Corp**) and its controlled entities (the **Group**).

iQ3Corp provided investment banking services to GBS for both pre-IPO round and IPO round. In Dec 2020, GBS was successfully listed on Nasdaq with an over-subscribed IPO. This is a significant achievement for iQ3Corp.

As of today, iQ3Corp owns 100% of iQ Capital, a New York based investment banking business dedicated to realizing healthcare transactions. In addition, iQ3Corp owns 40.5% of TEX Core oncology platform, an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug resistant solid tumors. OncoTEX to date has a pipeline of three compounds, one in preclinical phase transitioning to Phase 1 within 2021 and 2 more compounds at discovery phase, transitioning to preclinical development.

Revenue in FY20 was \$6,899,968 compared to \$6,160,849 in the prior corresponding period. This represented a 12% increase in revenue. The Group has performed solidly during the year, seizing the opportunities presented by the current challenging market conditions as a result of the COVID-19 pandemic.

The net loss after tax of the Group for the year ended 30 June 2020 was \$2,212,596 (FY19: \$1,098,530). The increase in losses were largely driven by an increase in employee related expenses (incorporated within costs of sales), as the Group continues to incur expenditure required for investing in the infrastructure to execute the Group's strategy. These investments, including the acquisition and licensing of life science assets for new and existing clients, are expected to generate greater levels of corporate advisory work for iQ3Corp in future years. iQ3Corp is uniquely positioned to capitalise on these opportunities.

Finally, I would like to thank my fellow Directors and the executive management team for the continuing commitment and professionalism they have displayed

during the year. Without this dedicated team of individuals, we could not deliver the core mandate of making a difference in the Australian life science sector by facilitating access to capital markets in Australia and giving this sector the opportunity to become a major force globally.

END